Fed. Circ. Won't Rehear IP Suit Over Hanmi's Nexium Generic

Law360, Los Angeles (February 26, 2014, 9:36 PM EST) -- The Federal Circuit on Tuesday refused AstraZeneca AB’s request for an en banc rehearing of its patent dispute over Hanmi Pharmaceutical Co. Ltd.'s generic version of AstraZeneca's acid reflux drug Nexium, stymying AstraZeneca's efforts to block the generic.

In a brief order that wasn't accompanied by an opinion, the appeals court shot down the petitions by AstraZeneca, which has argued that a Federal Circuit panel disregarded precedent in upholding a lower court’s claim construction, for a panel rehearing and a rehearing en banc.

Mark Boland of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.